Because the most robust RIPK3 expression loss was observed in ovarian cancer biopsies (Fig 1A), we performed a newly derived patient-derived xenograft (PDX) study using primary cells obtained from high-grade serous ovarian cancer biopsies, in order to determine whether necroptosis is physiologically activated in tumors and whether RIPK3 protein levels indeed are lost during tumorigenesis progression. This evidence concerns the gene RIPK3 and ovarian cancer.